Outcomes in 144 patients with colorectal cancer treated in a phase i clinic: The MD anderson cancer center experience

Clinical Colorectal Cancer

Volumn 11, Issue 4, 2012, Pages 297-303

  Hong, David S ^a   Patel, Jesal C ^a   Wheler, Jennifer ^a   Naing, Aung ^a   Garrido Laguna, Ignacio ^a   Falchook, Gerald ^a   Fu, Siqing ^a   Tsimberidou, Apostolia M ^a   Kopetz, Scott ^a   Win, Sijin ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; IRINOTECAN; PANITUMUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER CARE FACILITIES; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; PROGNOSIS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84868361922     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2012.02.001     Document Type: Article

References (21)

1. A. Jemal, R. Siegel, E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. S. Edge, D.R. Byrd, C.C. Compton AJCC cancer staging Manual 7th ed. 2010 Springer New York
3. P.C. Simmonds Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis Colorectal Cancer Collaborative Group BMJ 321 2000 531 535
4. S. Kopetz, G.J. Chang, M.J. Overman Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy J Clin Oncol 27 2009 3677 3683
5. E.A. Eisenhauer, P.J. O'Dwyer, M. Christian Phase I clinical trial design in cancer drug development J Clin Oncol 18 2000 684 692
6. H.T. Arkenau, D. Olmos, J.E. Ang 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer 44 2008 1536 1540
7. T. Bachelot, I. Ray-Coquard, G. Catimel Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials Ann Oncol 11 2000 151 156
8. C. Han, J.P. Braybrooke, G. Deplanque Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents Br J Cancer 89 2003 1166 1171
9. E. Horstmann, M.S. McCabe, L. Grochow Risks and benefits of phase 1 oncology trials, 1991 through 2002 N Engl J Med 352 2005 895 904
10. R.K. Jain, J.J. Lee, D. Hong Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse Clin Cancer Res 16 2010 1289 1297
11. H.T. Arkenau, J. Barriuso, D. Olmos Prospective validation of a prognostic score to improve patient selection for oncology phase I trials J Clin Oncol 27 2009 2692 2696
12. H.T. Arkenau, D. Olmos, J.E. Ang Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience Br J Cancer 98 2008 1029 1033
13. I. Garrido-Laguna, F. Janku, G.S. Falchook Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment Clin Cancer Res 16 2010 4031 4037
14. A.M. Tsimberidou, C. Vaklavas, S. Wen Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience J Clin Endocrinol Metab 94 2009 4423 4432
15. H.T. Arkenau, A.T. Brunetto, J. Barriuso Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer Oncology 76 2009 151 156
16. E.A. Eisenhauer, P. Therasse, J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
17. E.L. Kaplan, P. Meier Nonparametric estimator from incomplete observations J Am Stat Assoc 53 1958 457 481
18. D.R. Cox Regression models and life-tables J R Stat Soc Series B Stat Methodol 34 1972 187 220
19. K.T. Flaherty, I. Puzanov, K.B. Kim Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
20. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med; 363:1693-703.
21. A.M. Tsimberidou, N.G. Iskander, D.S. Hong Personalized medicine in a phase I clinical trials program: the M. D. Anderson Cancer Center Initiative J Clin Oncol 29 suppl 2011 abstract CRA2500